Hyperion Clal Biotech Resolve Dispute Over Diabetes Drug
Biotechnology News
JERUSALEM (Reuters) - Hyperion Therapeutics and Clal Biotechnology Industries said they agreed to resolve their dispute after Hyperion halted development of a diabetes drug it bought from Clal due to manipulation of trial data. Hyperion had bought Israel's Andromeda Biotech - which is developing DiaPep277, a treatment for Type I diabetes that is undergoing a second advanced clinical study - from Clal for $12.5 million in June. The deal included milestone payments reaching $570 million. But in September, U.S. ...
Source